IRADIMED CORPORATION To Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02 2024 - 4:30PM
IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leader in
developing innovative Magnetic Resonance Imaging (“MRI”) compatible
medical devices, today announced that the Company will be
participating in the upcoming 42nd Annual J.P. Morgan Healthcare
Conference.
Iradimed’s CEO, Roger Susi, is scheduled to present
on Thursday, January 11, 2024, at 12:00 p.m. Pacific Time.
Interested parties may access a live and archived webcast of the
presentation on the “Events and Presentations” section of the
Company’s investor website at
https://www.iradimed.com/investors/events.
About IRADIMED
CORPORATION
IRADIMED CORPORATION is a leader in developing
innovative Magnetic Resonance Imaging (“MRI”) compatible medical
devices. We design, manufacture, market, and distribute
MRI-compatible medical devices, accessories, disposables, and
related services.
We are the only provider of a non-magnetic
intravenous (“IV”) infusion pump system designed to be safe during
MRI procedures. We were the first to develop an infusion delivery
system to eliminate many dangers and problems during MRI
procedures. Standard infusion pumps contain magnetic and electronic
components that can create radio frequency interference and are
dangerous to operate in the presence of the powerful magnet that
drives an MRI system. Our patented MRidium® MRI-compatible IV
infusion pump system has a non-magnetic ultrasonic motor, uniquely
designed non-ferrous parts, and other unique features to deliver
anesthesia safely and predictably and other IV fluids during
various MRI procedures. Our pump solution provides a seamless
approach that enables accurate, safe, and dependable fluid delivery
before, during, and after an MRI scan, which is essential to
critically ill patients who cannot be removed from their vital
medications and children and infants who must generally be sedated
to remain immobile during an MRI scan.
Our 3880 MRI-compatible patient vital signs
monitoring system has been designed with non-magnetic components
and other unique features to monitor a patient’s vital signs safely
and accurately during various MRI procedures. The IRADIMED 3880
system operates dependably in magnetic fields up to 30,000 gauss,
which means it can work virtually anywhere in the MRI scanner room.
The IRADIMED 3880 has a compact, lightweight design, allowing it to
travel with the patient from the critical care unit to the MRI and
back, resulting in increased patient safety through uninterrupted
vital signs monitoring and decreasing the amount of time critically
ill patients are away from critical care units. The features of the
IRADIMED 3880 include wireless ECG with dynamic gradient filtering;
wireless SpO2 using Masimo® algorithms; non-magnetic respiratory
CO2; invasive and non-invasive blood pressure; patient temperature,
and optional advanced multi-gas anesthetic agent unit featuring
continuous Minimum Alveolar Concentration measurements. The
IRADIMED 3880 MRI-compatible patient vital signs monitoring system
has an easy-to-use design and effectively communicates patient
vital signs information to clinicians.
For more information, please visit
www.iradimed.com.
Media Contact:John Glenn Chief Financial
OfficerIRADIMED CORPORATION(407)
677-8022InvestorRelations@iradimed.com
iRadimed (NASDAQ:IRMD)
Historical Stock Chart
From Oct 2024 to Nov 2024
iRadimed (NASDAQ:IRMD)
Historical Stock Chart
From Nov 2023 to Nov 2024